Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
Metrics to compare | INIT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINITPeersSector | |
---|---|---|---|---|
P/E Ratio | −13.4x | −3.1x | −0.5x | |
PEG Ratio | −0.35 | −0.15 | 0.00 | |
Price/Book | 12.7x | 2.7x | 2.6x | |
Price / LTM Sales | - | 13.7x | 3.3x | |
Upside (Analyst Target) | 301.8% | 351.4% | 40.1% | |
Fair Value Upside | Unlock | 1.0% | 5.1% | Unlock |